In Case You Missed It: Weekly Equity Market Commentary & Conviction Calls

Research evidence excerpt

In Case You Missed It: Weekly Equity Market Commentary & Conviction Calls

Equity Research

Equity PMG

18 June 2026

In Case You Missed It

Weekly Equity Market

Commentary & Conviction Calls

While the US-Iran deal announcement was a positive for

U.S. Equity Product Management

equities in the holiday-shortened week, Wednesday's FOMC Group

meeting tempered the enthusiasm slightly given the hawkish Terence Malone* + 1 212 526 7578

turn under Chair Warsh, leading to increased expectations of terence.malone@barclays.com

a potential rate hike this year. BCI, US

Andrew Ferremi*

+1 212 526 8257

andrew.ferremi@barclays.com

Research Conviction Calls BCI, US

Hims & Hers Health: Our Proprietary Data Points to Sharp Inflection; Reit OW PT to

$39 (06/17/2026). Glen Santangelo notes that early traction from the Novo partnership has been

robust, with >125,000 Wegovy shipments fulfilled within six weeks of introduction, strong

conversion to branded therapy, and high engagement, reflecting patient willingness to pay for

clinically validated, safe, and effective therapies. Moreover, his alternative data has started to

show improvement in the time since the partnership was announced on March 9. There has

been a positive inflection in April (+12% y/y) followed by even stronger traffic in May (+35% y/y).

As for his proprietary Barclaycard data, the number of transactions is improving on a sequential

basis, and total spend is up – which he believes is partially a function of the switch from multi-

month subscriptions to a single-month model for the branded GLP-1s. In addition, he expects

growth broadening beyond weight loss, as he sees testosterone, easing sexual health

headwinds, and international expansion all playing a role with peptides as the next catalyst.